Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)Panagiota Economopoulou, Amanda Psyrri, Μaria Anastasiou et al.|Cancers|2021Cited by 29
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patientsAntonios Valachis, Thanos Kosmidis, R. Gomez-Bravo et al.|Future Oncology|2024Cited by 11
Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC).Panagiota Economopoulou, Amanda Psyrri, Nikolaos Spathas et al.|Journal of Clinical Oncology|2019Cited by 4